
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


FibroGen Inc (FGEN)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: FGEN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $43
1 Year Target Price $43
0 | Strong Buy |
1 | Buy |
1 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 1.32% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 45.01M USD | Price to earnings Ratio - | 1Y Target Price 43 |
Price to earnings Ratio - | 1Y Target Price 43 | ||
Volume (30-day avg) 2 | Beta 0.77 | 52 Weeks Range 4.50 - 21.94 | Updated Date 08/29/2025 |
52 Weeks Range 4.50 - 21.94 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -21.61 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-11 | When - | Estimate -0.09 | Actual -1.88 |
Profitability
Profit Margin -28.12% | Operating Margin (TTM) -864.91% |
Management Effectiveness
Return on Assets (TTM) -16.4% | Return on Equity (TTM) -1015.79% |
Valuation
Trailing PE - | Forward PE 61.35 | Enterprise Value 95374595 | Price to Sales(TTM) 6.13 |
Enterprise Value 95374595 | Price to Sales(TTM) 6.13 | ||
Enterprise Value to Revenue 12.63 | Enterprise Value to EBITDA -0.17 | Shares Outstanding 4043900 | Shares Floating 3623697 |
Shares Outstanding 4043900 | Shares Floating 3623697 | ||
Percent Insiders 1.58 | Percent Institutions 26.54 |
Upturn AI SWOT
FibroGen Inc

Company Overview
History and Background
FibroGen, Inc. is a biopharmaceutical company founded in 1993. It focuses on the discovery, development, and commercialization of therapeutics to treat fibrosis, anemia, and cancer. A significant milestone was the approval and launch of roxadustat for anemia in various countries outside the U.S.
Core Business Areas
- Pharmaceutical Development: FibroGen focuses on researching and developing novel therapeutics for unmet medical needs in fibrosis, anemia, and oncology.
- Commercialization Partnerships: The company collaborates with pharmaceutical partners like AstraZeneca and Astellas to commercialize its products globally.
Leadership and Structure
FibroGen is led by a management team with expertise in drug development and commercialization. The company's organizational structure includes research and development, clinical operations, and commercial functions.
Top Products and Market Share
Key Offerings
- Roxadustat: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of anemia associated with chronic kidney disease (CKD). While approved in Europe, China, Japan, and other regions, its approval in the U.S. has faced challenges. Competitors include erythropoiesis-stimulating agents (ESAs) like epoetin alfa (Amgen's Epogen/Procrit) and darbepoetin alfa (Amgen's Aranesp). Market share data varies by region and indication. Revenue varies based on partnerships and regional sales. No current market share number in the US.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for anemia treatments is mature but with growing demand for novel therapies.
Positioning
FibroGen is positioned as an innovator in the development of HIF-PH inhibitors for anemia. Its competitive advantage lies in its novel oral drug, roxadustat, which offers a convenient alternative to injectable ESAs.
Total Addressable Market (TAM)
The global anemia market is substantial and expected to grow. While a specific TAM isn't provided here, FibroGen aims to capture a significant share of the CKD-associated anemia market with roxadustat.
Upturn SWOT Analysis
Strengths
- Novel HIF-PH inhibitor technology
- Established partnerships with major pharmaceutical companies
- Roxadustat approved in multiple regions
Weaknesses
- Regulatory setbacks in the U.S.
- Reliance on partnerships for commercialization
- Limited product portfolio
Opportunities
- Expansion into new indications for roxadustat
- Development of new therapeutics in fibrosis and oncology
- Potential for U.S. approval of roxadustat
Threats
- Competition from existing anemia treatments (ESAs)
- Regulatory hurdles and clinical trial risks
- Patent expirations and generic competition
Competitors and Market Share
Key Competitors
- AMGN
- MRK
- SNY
Competitive Landscape
FibroGen's advantage lies in its oral HIF-PH inhibitor technology, but it faces intense competition from established ESAs and biosimilars. A U.S. approval of roxadustat is vital to their competitive landscape.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by the development and commercialization of roxadustat outside the U.S.
Future Projections: Future growth depends on the success of roxadustat in existing markets, potential U.S. approval, and the development of new pipeline products. Analyst estimates vary based on these factors.
Recent Initiatives: Recent initiatives include efforts to address regulatory concerns in the U.S. and expand the development of pipeline assets.
Summary
FibroGen is a biopharmaceutical company with an innovative technology in HIF-PH inhibition. Roxadustat's approval in many regions is a success. However, regulatory challenges in the US remain an obstacle. Further pipeline success is crucial. Competition in the anemia market is intense, presenting both threats and opportunities for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Press releases
- Financial News Sources
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data are estimates and may vary. Financial data needs to be dynamically gathered from financial news sources.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About FibroGen Inc
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 2014-11-14 | CEO & Director Mr. Thane Wettig | ||
Sector Healthcare | Industry Biotechnology | Full time employees 225 | Website https://www.fibrogen.com |
Full time employees 225 | Website https://www.fibrogen.com |
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.